PDZ Ligand: A Potential Drug Target for Neurological Disorders

Target Name: NOS1AP

NCBI ID: G9722

NOS1AP

Other Name(s): C-terminal PDZ ligand of neuronal nitric oxide synthase protein | nitric oxide synthase 1 adaptor protein | Nitric oxide synthase 1 adaptor protein, transcript variant 2 | Nitric oxide synthase 1 adaptor protein, transcript variant 3 | CAPON_HUMAN | Nitric Oxide Synthase 1 (Neuronal) Adaptor Protein | Carboxyl-terminal PDZ ligand of neuronal nitric oxide synthase protein (isoform 1) | nitric oxide synthase 1 (neuronal) adaptor protein | Carboxyl-terminal PDZ ligand of neuronal nitric oxide synthase protein (isoform 3) | Nitric oxide synthase 1 adaptor protein | NPHS22 | Carboxyl-terminal PDZ ligand of neuronal nitric oxide synthase protein | Nitric oxide synthase 1 adaptor protein, transcript variant 1 | CAPON | Nitric oxide synthase 1 (neuronal) adaptor protein | C-terminal PDZ domain ligand of neuronal nitric oxide synthase | Carboxyl-terminal PDZ ligand of neuronal nitric oxide synthase protein (isoform 2) | ligand of neuronal nitric oxide synthase with carboxyl-terminal PDZ domain | KIAA0464 | NOS1AP variant 1 | NOS1AP variant 2 | 6330408P19Rik | Ligand of neuronal nitric oxide synthase with carboxyl-terminal PDZ domain | C-terminal PDZ domain ligand of neuronal nitric oxide synthase (CAPON) | NOS1AP variant 3

PDZ Ligand: A Potential Drug Target for Neurological Disorders

Neuronal Nitric Oxide Synthase (NOS) is a protein that plays a crucial role in the production of nitric oxide (NO) in the nervous system. Nitric oxide is a potent signaling molecule that plays a key role in the regulation of blood flow, pain perception, and neurotransmitter release. The C-terminal region of the NOS protein is known as the PDZ ligand, which is a protein that can interact with the PDZ domain of other proteins. This interaction has been identified as a potential drug target for the treatment of various neurological and psychiatric disorders.

The PDZ domain is a protein-coding region that is located in the C-terminus of the NOS protein. It is characterized by a conserved sequence that includes a heptadecylated cysteine residue, a negatively charged amino acid (D), and a hypervariable region (HVR). The PDZ domain is thought to play a key role in the regulation of protein stability and localization.

The C-terminal region of the NOS protein is also known as the NOS1 region. It is a 120 amino acid long sequence that is located between the A and C terminals of the NOS protein. The NOS1 region is highly conserved and is involved in the regulation of various cellular processes, including cell signaling, cytoskeletal organization, and protein stability.

The PDZ ligand is a small protein that is located in the C-terminus of the NOS1 region of the NOS protein. It is characterized by a variable region that includes a heptadecylated cysteine residue, a negatively charged amino acid (D), and a hypervariable region (HVR). The PDZ ligand is thought to interact with the PDZ domain of other proteins through its ability to form a covalent complex with the negatively charged amino acid (D) residue.

The PDZ ligand has been shown to play a role in the regulation of various cellular processes, including the production of nitric oxide (NO), cell signaling, and neurotransmission. For example, studies have shown that the PDZ ligand can interact with the PDZ domain of the protein Pyruvatecarrierprotein (Pcp) to regulate the production of NO by the enzyme Nitric Oxide Synthase (NOS).

In addition to its role in the regulation of NO production, the PDZ ligand has also been shown to play a role in the regulation of cell signaling. For example, studies have shown that the PDZ ligand can interact with the PDZ domain of the protein Transthyretin (Ttr) to regulate the production of NO by the enzyme Nitric Oxide Synthase (NOS).

The PDZ ligand has also been shown to play a role in the regulation of neurotransmission. For example, studies have shown that the PDZ ligand can interact with the PDZ domain of the protein Endothelial Nitric Oxide Synthase (EndoNO) to regulate the production of NO by the enzyme Nitric Oxide Synthase (NOS).

The PDZ ligand is also a potential biomarker for the diagnosis and treatment of various neurological and psychiatric disorders. For example, studies have shown that the PDZ ligand is downregulated in the brains of individuals with Alzheimer's disease, which is a progressive neurodegenerative disorder that is characterized by the accumulation of neurofibrillary tangles and the loss of brain cells. This suggests that the PDZ ligand may be a potential drug target for the treatment of Alzheimer's disease.

In conclusion, the PDZ ligand of the NOS protein is a highly conserved protein that plays a crucial role in the regulation of various cellular processes, including the production of nitric oxide (NO), cell signaling, and neurotransmission. Its interaction with other proteins through the PDZ domain has been shown to play a key role in these processes. The PDZ ligand is also a potential drug target for the treatment of various neurological and psychiatric disorders. Further research is needed to fully understand the role of the PDZ ligand in these processes and to develop effective treatments.

Protein Name: Nitric Oxide Synthase 1 Adaptor Protein

Functions: Adapter protein involved in neuronal nitric-oxide (NO) synthesis regulation via its association with nNOS/NOS1. The complex formed with NOS1 and synapsins is necessary for specific NO and synapsin functions at a presynaptic level. Mediates an indirect interaction between NOS1 and RASD1 leading to enhance the ability of NOS1 to activate RASD1. Competes with DLG4 for interaction with NOS1, possibly affecting NOS1 activity by regulating the interaction between NOS1 and DLG4 (By similarity). In kidney podocytes, plays a role in podosomes and filopodia formation through CDC42 activation (PubMed:33523862)

The "NOS1AP Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NOS1AP comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets